Active	Status	Sponsor type	Region	Phase	Filter
2 Active 3 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
recombinant human alkaline phosphatase intravenous (recAP) / AM Pharma
2019-004625-24: Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated Acute Kidney Injury	Not yet recruiting	3	1600	Europe, RoW	Recombinant Human Alkaline Phosphatase, recAP, Solution for infusion	AM-Pharma B.V., AM-Pharma B.V.	Sepsis-associated acute kidney injury, Sepsis-associated acute kidney injury, Body processes [G] - Immune system processes [G12]
NCT05890794: Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia	Completed	1/2	12	Europe	Ilofotase Alfa, 0.8 mg/kg, recAP, Ilofotase Alfa, 3.2 mg/kg	AM-Pharma	Hypophosphatasia	07/23	07/23